The findings indicated that xenograft prostate cancer tumors derived from 22Rv1 or DU145 cells with stable ZMYND11 silencing exhibited significantly enhanced growth compared to xenografts from control cells (Fig. 2f and Supplementary Fig. 2f). The gene discussed is ZMYND11; the disease is prostate carcinoma.